|
Market Closed -
Australian S.E.
04:10:14 11/09/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 167.10 AUD | -1.42% |
|
-4.24% | -3.21% |
| 11/09 | CSL Seqirus Publishes Phase 3 Study Results for Influenza Vaccine | MT |
| 09/09 | Australian shares post six-week closing low as banks drag | RE |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 89,299 | 89,052 | 95,184 | 76,024 | 38,015 | 57,395 | - | - |
| Change | - | -0.28% | 6.89% | -20.13% | -50% | 50.98% | - | - |
| Enterprise Value (EV) 1 | 88,520 | 99,731 | 105,710 | 85,005 | 47,398 | 66,326 | 65,858 | 65,220 |
| Change | - | 12.66% | 5.99% | -19.59% | -44.24% | 39.93% | -0.71% | -0.97% |
| P/E | 38.6x | 40.8x | 36.1x | 25.4x | -14.8x | 19.6x | 17.8x | 17x |
| PBR | 6.13x | 5.64x | 5.48x | 3.93x | 2.57x | 3.56x | 3.26x | 2.96x |
| PEG | - | -7.25x | 1.8x | 1.9x | 0x | -0x | 1.7x | 3.45x |
| Capitalization / Revenue | 8.45x | 6.69x | 6.43x | 4.89x | 2.41x | 3.64x | 3.52x | 3.38x |
| EV / Revenue | 8.38x | 7.49x | 7.14x | 5.46x | 3x | 4.21x | 4.04x | 3.84x |
| EV / EBITDA | 24.6x | 25.6x | 22.3x | 16.5x | 10.7x | 13.1x | 12.4x | 11.7x |
| EV / EBIT | 30.2x | 32.5x | 27.7x | 19x | 10.3x | 15.1x | 14.3x | 13.5x |
| EV / FCF | 57.1x | 72.6x | 55.2x | 29.1x | 16.5x | 21.2x | 22.4x | 21.1x |
| FCF Yield | 1.75% | 1.38% | 1.81% | 3.44% | 6.05% | 4.72% | 4.46% | 4.74% |
| Dividend per Share 2 | 2.22 | 2.36 | 2.64 | 2.92 | 2.92 | 3 | 3.182 | 3.408 |
| Rate of return | 1.2% | 1.28% | 1.34% | 1.86% | 3.68% | 2.5% | 2.65% | 2.84% |
| EPS 2 | 4.8 | 4.53 | 5.45 | 6.17 | -5.35 | 6.1 | 6.724 | 7.056 |
| Distribution rate | 46.3% | 52.1% | 48.4% | 47.3% | -54.6% | 49.2% | 47.3% | 48.3% |
| Net sales 1 | 10,562 | 13,310 | 14,800 | 15,558 | 15,797 | 15,762 | 16,311 | 17,000 |
| EBITDA 1 | 3,596 | 3,900 | 4,750 | 5,151 | 4,438 | 5,073 | 5,308 | 5,580 |
| EBIT 1 | 2,927 | 3,069 | 3,812 | 4,468 | 4,620 | 4,380 | 4,597 | 4,830 |
| Net income 1 | 2,255 | 2,194 | 2,642 | 3,002 | -2,579 | 2,837 | 3,166 | 3,368 |
| Net Debt 1 | -778.6 | 10,679 | 10,526 | 8,981 | 9,383 | 8,931 | 8,463 | 7,825 |
| Reference price 2 | 185.38 | 184.61 | 196.96 | 157.01 | 79.38 | 119.85 | 119.85 | 119.85 |
| Nbr of stocks (in thousands) | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | 478,912 | - | - |
| Announcement Date | 16/8/22 | 14/8/23 | 12/8/24 | 18/8/25 | 17/8/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.65x | 4.21x | 13.08x | 2.5% | 57.4B | |
| 18.1x | 4.19x | 9.84x | 0.5% | 78.04B | |
| -17.17x | 25.62x | -16.63x | -.--% | 57.48B | |
| 34.47x | 11.73x | 22.49x | -.--% | 48.81B | |
| 20.54x | 4.54x | 12.95x | 0.71% | 45.5B | |
| 37.49x | 3.54x | 13.51x | -.--% | 32.08B | |
| 54.21x | 3.43x | 26.59x | -.--% | 24.62B | |
| 62.21x | 6.52x | 39.5x | -.--% | 20.77B | |
| 22.98x | 4.94x | 12.86x | -.--% | 15.75B | |
| -26.83x | 14.96x | -40.16x | -.--% | 14.16B | |
| Average | 22.56x | 8.37x | 9.40x | 0.37% | 39.46B | |
| Weighted average by Cap. | 20.23x | 8.73x | 9.61x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Select your edition
All financial news and data tailored to specific country editions
